

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

COMPLETION OF TRANSACTIONS WITH SANDOZ INVOLVING (1) THE ACQUISITION OF SANDOZ’S CHINESE SUBSIDIARY AND (2) THE DISPOSAL TO SANDOZ OF FOUR ANAESTHETIC PRODUCTS IN EUROPE

Shareholders are referred to the announcement of 4 December 2023 wherein it was confirmed that Aspen had concluded an agreement with Sandoz AG (“Sandoz”), in terms of which Aspen will:

- acquire from Sandoz the entire share capital of its subsidiary, Sandoz (China) Pharmaceutical Co., Ltd. (“Sandoz China” and “the Company”), together with the commercialisation rights and related intellectual property for:
 - a portfolio of established products currently commercialised by the Company; and
 - a pipeline of products to be launched by the Company in the short to medium term
- dispose to Sandoz of the commercialisation rights and related intellectual property for four anaesthetic products currently sold by Aspen in the European Economic Area.

Aspen is pleased to confirm that the required merger authority approval for the above transactions has been granted by the Chinese Authority (State Administration for Market Regulation) and that both of the transactions are anticipated to become effective by the end of the current financial year.

Durban
04 April 2024

Sponsor
Investec Bank Limited